Joby Aviation closes $591 million stock offering with full underwriter option
Eric Mosbrooker, Chief Commercial Officer of Avidity Biosciences NASDAQ:RNA, a $6.5 billion market cap biotech company, sold 6,563 shares of common stock on September 3, 2025, at prices ranging from $46.13 to $47.66, netting approximately $308,935. The stock has since climbed to $50.36, marking a 73% gain year-to-date.
The same day, Mosbrooker also exercised options to acquire 6,563 shares of Avidity Biosciences stock at a price of $9.05, for a total value of $59,395.
Following these transactions, Mosbrooker directly owns 55,000 shares of Avidity Biosciences.
The sales were executed under a pre-arranged 10b5-1 trading plan adopted on September 11, 2024.
In other recent news, Avidity Biosciences has completed enrollment for its global Phase 3 HARBOR clinical trial of delpacibart etedesiran for myotonic dystrophy type 1. The company expects topline data from this trial in the second quarter of 2026 and plans to submit marketing applications in the United States, European Union, and Japan later that year. In another development, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to Avidity’s delpacibart zotadirsen for treating Duchenne muscular dystrophy. This designation aims to expedite the development and review process for drugs that show significant improvement over existing therapies.
Furthermore, Goldman Sachs has resumed coverage on Avidity Biosciences with a Buy rating, citing a positive outlook on the company’s platform technology. Cantor Fitzgerald reiterated its overweight rating on Avidity, expressing confidence in the company’s leadership and their efforts in developing treatments for rare muscle diseases. These developments reflect the growing interest and positive sentiment from analysts regarding Avidity’s potential in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.